HUTCHMED (China) Limited (HCM) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello everyone, this is David Nguyen, head of investor relation of HodgeMet. Thank you for joining HodgeMet 2025 interim result presentation. Our results and presentation slides have already been posted on our homepage, as well as on the Hong Kong Stock Exchange website. Just a quick moment on the disclaimer. The performance and results of operation of HodgeMet Group contained within this presentation are historical in nature, and past performance is no guarantee of future results, and actual result may vary materially from those set forth in the forward-looking statement. So today we are very glad to have our CEO, Dr. Su, our CFO, Mr. Chan, our CMO, Dr. Shi and our head of commercial, Mr. Yuan, to go over the results and provide the latest update on our performance. And the projects and the development. As usual, we will have a Q&A session at the very end, when you can press the raise head button to ask questions and or type in the chat box, but please make sure you have your name and your company name on the screen. So now let us welcome our chief executive officer and chief scientific officer, Dr. Wei-Wu Su to begin our presentation. Dr. Su. Thank you, David. If we go to the next slide. So again, good evening, good morning, everyone. Welcome to the HatchMet Major Results Conference call. The highlights for the first half 2025, global commercial success for Zagla continues to grow. First half, up 25% comparing to 2024 or PASSES or Savalitinib, potentially our second global commercial product. There are filings ongoing based on Savannah in some countries and also obviously the global registration of study, CEPHRON study is recruiting. We anticipate completion of recruitment later this year. And of course, Elunate in China, new indications, endometrial cancer approve...